Nuovo
GenBody Rapid COVID-19 Ag Test
0 Recensioni
Pubblicato Di RCS Healthcare
$77.50 (USD)
- Posizione: United States
- Stato: Disponibile
Detagli
The GenBody COVID-19 Ag point-of-care **** is a lateral flow chromatographic immunoassay intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus.
Features & Benefits
FDA EUA Authorized rapid antigen ****
Anterior nasal swab specimen collection for comfort
Identifies acute infection with a 92.31% sensitivity and 99.04% specificity
Selected by NIH for the Rapid Acceleration of Diagnostics, for US production of the GenBody COVID-19 Ag ****
Large manufacturing capacity and immediately available for distribution
For use in the Point-of-Care setting
prodotti correlati
